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ABSTRACT
Aging is a major risk factor for metabolic syndromes and type two diabetes. With
growing elderly populations worldwide and increasing incidence of age-related diseases there is
a great need to develop pharmacological interventions that would delay aging and protect from
age-related diseases. 17-alpha estradiol (17α-E2) is an epimer of the primary female sex
hormone estradiol and has been shown to extend lifespan and downregulate markers of agerelated metabolic dysfunction in male mice. Because 17α-E2 does not induce feminization in
males it holds potential as a novel therapeutic in humans for age-related metabolic dysfunction.
Importantly, we have previously shown that 17α-E2 causes an increase of circulating and hepatic
IGF-1 in aged mice, without any changes in GH release in treated animals. Based on this we
propose a new hypothesis that 17α-E2 acts through a novel, GH-independent pathway
stimulating production of IGF-1 and positively modulating metabolic function in a sex-specific
manner. Here we studied 17α-E2 treated long-lived growth hormone receptor knockout
(GHRKO) mice, characterized by severely reduced circulating and hepatic IGF-1 due to GHresistance. We found increases in circulating IGF-1 after treatment in normal and GHRKO male
mice, with no effect in female mice, which supports our hypothesis that 17α-E2 induces GH
independent IGF-1 production. To determine novel genetic pathways activated by 17α-E2 we
performed sequencing of hepatic RNA. Our analysis indicated differential regulation of steroid
biosynthesis and insulin signaling pathways. The validation of our sequencing data using qPCR
showed significant upregulation of genes involved in insulin action. Importantly, differential
regulation of these pathways was present in normal male mice, with no changes in normal
females or either male or female GHRKO animals. In summary, this new data supports our
iii

hypothesis of a sex-specific effect of 17α-E2 treatment and differing mechanisms of action by
which 17α-E2 upregulates IGF-1 independently of GH action.
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CHAPTER ONE: INTRODUCTION
Metabolic dysfunction, particularly type two diabetes and obesity prevalence, increases
with age leading to increased healthcare costs and gives rise to numerous secondary health issues
(1, 2). Interventions in the form of calorie restriction have proven effective in humans but
pharmaceutical interventions are more desirable as they are easier to implement and have higher
retention rates (3). With advances in healthcare the human population is living longer and thus
there is a great need to develop new pharmacological interventions that would delay aging and
protect from age-related metabolic diseases.
To further investigate possible treatments for age-related diseases and to examine how
healthy lifespan (healthspan) can be extended in humans, the National Institutes of Aging (NIA)
has created the Interventions Testing Program, which studies agents with the potential to extend
lifespan and delay metabolic dysfunction with age. Agents of interest are tested at three separate
sites using identical standardized protocols and results are pooled yielding robust statistical
significance. One such agent from this program found to extend healthspan is 17α-E2. The
female hormone 17α-E2 is a stereoisomer of the primary female sex hormone 17β-E2, the most
potent estrogen hormone in circulation, differing from its epimer by the orientation of a hydroxyl
group which causes a decreased affinity for the classical estrogen receptors, ERα and ERβ. 17αE2 is naturally occurring in females and males and because of the aforementioned decreased
affinity does not induce female characteristics in males. Studies have shown that 17α-E2
treatment alleviates age related metabolic dysfunction in mice (4) extends median lifespan in
male mice (5, 6), and more recently the positive metabolic effects of 17α-E2 have been
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associated with the production of testicular hormones in adult life (7). Since 17α-E2 is nonfeminizing and given the link between lifespan extension and metabolism it holds potential as a
novel therapeutic in humans for age-related metabolic dysfunction.
The focus of our research group is how modulation of the GH/IGF1 axis can contribute to
life and health span extension. The GH/IGF1 axis has been shown to be the most conserved
pathway affecting lifespan and manipulations to signaling have been shown to extend lifespan
(BARTKE citation). Since 17α-E2 has been previously shown to extend lifespan it is of interest
to us how 17α-E2 is affecting GH/IGF1 to extend lifespan.
We first studied the effects of 17α-E2 on GH/IGF1 signaling in C57B6 mice and
observed a GH independent increase in IGF1 production with treatment. This is a seminal
observation in the field of endocrinology as it is classically thought that IGF1 production is
explicitly linked to GH release. In order to pinpoint how exactly 17-aE2 is in fact inducing an
increase in IGF1 independent of GH we sought a model which has no GH. The growth hormone
receptor knockout (GHRKO) mouse provides the ideal setting to study this. These mice were
first described by Zhou et al in 1997 and are characterized by absence of the growth hormone
receptor (GHR) and GH binding protein and thus are growth hormone resistant (16). Important
to our study is the global lack of GHR as it guarantees that observed IGF1 increases with 17α-E2
treatment are independent from GH action and creates the ideal setting to test our hypothesis that
17α-E2 acts through a novel, GH-independent pathway stimulating production of IGF1 and
positively modulating metabolic function in a sex-specific manner. Our research examined the
effects of 17α-E2 treatment on the GH/IGF1 axis, genes downstream in the insulin and IGF1
signaling pathway and the extent of the effects of 17α-E2 on IGF1 production on hepatic tissue
2

to explore the mechanisms responsible for the previously observed lifespan extension and
alleviation of age-related metabolic dysfunction.
Given the demographic trends of increased longevity and consequent rise of metabolic
disorders with age and the important role that the GH/IGF1 axis plays in modulating lifespan an
increased understanding of the mechanism of action of 17α-E2 is useful. Thus, the main focus of
this study was to investigate the possible alternative regulation of GH/IGF1 signaling by 17α-E2.
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CHAPTER TWO: LITERATURE REVIEW
Growth Hormone/IGF1 Axis and Aging
Growth hormone is secreted by the anterior pituitary gland in response to several stimuli
which include growth hormone releasing hormone (GHRH), ghrelin and dietary stimuli. Its
secretion is controlled by a negative feedback loop with increased levels of IGF1 stimulating
decreased GH secretion. Briefly, GH release is stimulated by GHRH which is produced in the
hypothalamus. GH travels to the liver where it binds growth hormone receptors (GHR) leading
to the production of IGF1 by the liver. IGF1 travels through the bloodstream and acts on several
tissues including muscle and bone to promote growth. There is a negative feedback loop where
increases in IGF1 levels result in decreases in GHRH and thus decreases in release of GH.
Somatostatin inhibits GH release in response to GHRH (6). Thus, there is a direct pathway, with
regulation of hepatic IGF1 production by GH release and action.
It is important to note that GH is not continually secreted but secreted in bursts over the
day and this sort of release pattern is termed “pulsatile.” The pattern of GH release also differs
between females and males. In females, it is characterized by a continuous pattern of release but
in males GH is released in bursts separated by two hour intervals where GH release levels drop
to zero. (CITATION). These GH release cycles can be studied by drawing blood at consistent
time intervals over the day for a measure of GH pulsativity (8). The liver is the principle source
of IGF1 in the body with GH being the principle regulator of IGF1 production (9). IGF1 is a key
player in muscle growth, stimulates amino acid uptake and protein synthesis. The production of
IGF-1 has been classically inextricably linked with the action of GH. There have been
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discussions in the field of the possibility of varying GH control of IGF1 in tissues other than the
liver with some tissues displaying GH independent like production of IGF1, although possible
sources of extrahepatic circulating IGF1 is likely small and not well studied (10).
GH signaling is primarily through the Janus Kinase/Signal transducer and activator of
transcription (JAK/STAT) pathway and downstream of IGF1 signaling is the PI3-k/Akt pathway
including IRS-1, SOCS family of genes. There is heavy crosstalk between IGF1 and insulin
signaling.
With age, there are fluctuations in growth hormone levels and it is thought that decreases
in growth hormone levels contribute to aging. However, there have been several studies which
have attributed disruption in growth hormone (GH) signaling to lifespan extension, for instance
in the growth hormone receptor knockout mouse (11).

17-alpha Estradiol
17α-E2 is a naturally occurring hormone in both females and males with endogenous
levels being higher in females. 17α-E2 is weakly estrogenic and thus considered to be nonfeminizing. This is due to its decreased binding affinity for the classical estrogen receptors ERα
and ERβ. 17α-E2 needs to be distinguished from its isomer 17βE2 which is a potent feminizing
hormone. 17βE2 has been the subject of studies which emphasize its neuroprotective effects and
possible positive effects on cognition (12). 17α-E2 is a naturally occurring hormone and is
termed non-feminizing in that it does not induce female characteristics in males. Several
previous studies have examined the effect of 17α-E2 on lifespan as well as glucose homeostasis.
5

One such previous studies has shown up to a 20% increase in lifespan with 17α-E2 treatment
(13, 14). In others, authors have demonstrated that 17α-E2 improves glucose tolerance and
mTORC2 signaling (7). Of note, is that all these studies show positive effects of the 17α-E2
treatment only in males and not females.

Growth Hormone Receptor Knockout Mice
These mutant mice have a targeted inactivation of the Ghr gene which is
generated by the deletion of the 3’ portion of exon 4 and part of the downstream intron as
pioneered by Zhou et al. (15). Mice lacking GHR function serve as a model of human Laron
dwarf syndrome. Disruption of the GHR decreases IGF1 synthesis in the liver and stunts growth
in these mice so they are smaller than their normal littermates. These mice have very low levels
of IGF1 and increased levels of GH due to lack of negative feedback loop and subsequent
overproduction by the pituitary gland and have increased lifespan (16). These mice have been
studied previously are also characterized by numerous health benefits as previously described
herein, and they are particularly useful in this study as their mutation prevents the presence of
residual GH activity allowing us to pinpoint 17α-E2 regulation of IGF1 in these mice
independently of GH action

6

CHAPTER THREE: MATERIALS AND METHODS
Animals –Growth hormone receptor knockout (GHRKO) and normal mice were produced in the
lab of Dr. Andrejz Bartke of Southern Illinois University. C57B6 mice were housed in the lab of
Dr. Michael Stout of Oklahoma Health Sciences Center. GHRKO mice were produced by mating
heterozygous (GHR +/-) female carriers of the disrupted GHR/GH-binding protein gene with
knockout (GHR -/-) males. Animal procedures were performed at OUHSC and SIU in accordance
with their animal protocols.

17α-E2 Treatment– The first study was conducted in all male C57B6 mice beginning at 18
months of age and treatment continued for 15 weeks. Treatment in the GHRKO mice was
initiated at six months of age. Treatment was administered for four months following which
animals were euthanized and blood, plasma and tissue was collected and frozen at −80°C for
analysis. In both cohorts of mice studied, they were fed a diet containing 17α-E2 continuously
and had ad libitum access to food. 17α-E2 was mixed with their chow, prepared externally, at a
dose of 14.4 milligrams per kilogram diet (14.4 ppm) based on previous work (13).
For the GHRKO treatment cohort there was eight experimental groups: Normal Male
Control (NMC), Normal Male Estradiol (NME), GHRKO Male Control (KOMC), GHRKO
Male Estradiol (KOME), Normal Female Control (NFC), Normal Female Estradiol (NFE),
GHRKO Female Control (KOFC) and GHRKO Female Estradiol (KOFE). To each of these
groups 12 mice were initially assigned.
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GH Release Measurement - Pulsatile GH release was measured according to the protocol
described by Steyn et. al. briefly, tail-tip blood samples were collected from the animals at
regular intervals over the day and GH levels of whole blood were measured using a sensitive
sandwich ELISA

qPCR –Briefly, total RNA was extracted from liver tissue using Trizol and reverse transcribed to
cDNA using the iScript cDNA synthesis kit from Bio-Rad according to manufacturer’s protocol.
All the qPCR experiments were performed in replicates and beta-2 microglobulin (B2M) was
used as an endogenous control. All results are reported as the mean ± standard error of the mean
(SEM)

ELISA – Quantikine® ELISA Mouse/Rat IGF-1/IGF-1 Immunoassay from R &D Systems was
used to measure IGF1 levels in plasma. Plasma insulin levels were measured with the Mouse
Ultrasensitive Insulin ELISA from ALPCO. Hepatic total AKT1/2 and phosphorylated AKT
(pS473) were measured using the Multispecies InstantOneTM ELISA Kits, all from Thermo
Fischer Scientific. All ELISA kits were used according to manufacturer’s suggested protocol.

RNA Sequencing and Data Analysis – From each of the eight experimental groups, six animals
were randomly selected and RNA extracted from liver tissue, in the same process described for
qPCR analysis, for a total of 48 samples for RNA sequencing. RNA was extracted via a
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Trizol/Chloroform extraction and externally tested for RNA Integrity with all samples having an
RNA Integrity Number (RIN) greater than 6.9. Following quality control, library preparation and
sequencing was performed by Novogene.
The mapping of sequencing reads to the mouse transcriptome (Illumina iGenomes
annotation for UCSC mm10, http://support.illumina.com/sequencing/sequencing_software/
igenome.html) was performed using HiSat2 (17).The number of reads aligned to its
corresponding gene was calculated by HTSeq 0.6.1 (18). Genes with an average FPKM lower
than 1/100,000th of the total aligned reads in more than 50% of the samples were eliminated
from further analyses. Statistical analyses for differentially expressed mRNAs was performed
using the software R (3.2.2) and the Bioconductor package EdgeR (19) using the HTSeq output
count. Read counts were normalized for library depth, and pairwise comparisons, measuring fold
change, uncorrected P-values from the negative binomial distribution, and adjusted P values
(false discovery rate; FDR) were obtained. Principal components analysis (PCA) was also
performed using R to observe sample distribution in a two-dimensional plot and eliminate
outliers. Unsupervised hierarchical clustering was performed also using the DESeq package to
observe sample clustering. Genes with a FDR<0.05 and fold change (FC) >2.0 were considered
as up-regulated; and with FDR<0.05 and FC<0.5 were considered as down-regulated. mRNAs
were further processed for pathway analysis using the Generally Applicable Gene-set
Enrichment (GAGE), which uses log- based fold changes as per gene statistics, and Pathview
packages in R (20, 21). Enrichment of gene ontology (GO) terms (biological processes,
molecular function and cellular component) was also performed using the GAGE package. P
values lower than 0.05 were considered as significant for pathways and GO Terms analysis.
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Statistical Analysis – Data were compared using GraphPad Software (GraphPad Prism 8
Software for Windows) employing either a two-tailed Student’s T test or three-way analysis of
variance for genotype, treatment and interaction significance.
Table 1 – Primer sequences used for gene expression analysis
Genes
B2M
IGF1
PPARα
PPARγ
IRS1
Stat5b
SOCS2
mTOR
Akt2

Primer Sequences (forward and Reverse)
F: 5′-AAGTATACTCACGCCACCCA-3′
R: 5′-CAG CGCTATGTATCAGTCTC-3′
F: 5′-CTGAGCTGGTGGATGCTCTT-3′
R: 5′-CACTCATCCACACCTGT-3′
F: 5′-GTCAGTACTGTCGGTTTCAG-3′
R: 5′-CAGATCAGCAGACTCTGGGT-3′
F: 5′-GGGAAAGACCAGCAACC-3′
R: 5′-TGGAAGAATCGGACCTCTGC-3′
F: 5'-AGCCCAAAAGCCCAGGAGAATA-3'
R: 5'-TTTCGAGCCAGTCTCTTCTCTA-3'
F: 5'-AGA ATT TGC CAG GAC GGA ATT-3'
R: 5'-GAT AGC CCC ATC ATT CCA GTG A-3'
F: 5'- CTG CGC GAG CTC AGT CAA A -3'
R: 5'- ATC CGC AGGTTA GTC GGT CC -3'
F: 5'- CGG CAA CTT GAC CAT CCT CT -3'
R: 5'- TGCTGG AAG GCGTCA ATC TT -3'
F: 5-GAGGACCTTCCATGTAGACT-3′
R: 5′-CTCAGATGTGGAAGAGTGAC-3′
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CHAPTER FOUR: RESULTS
Results
GH Independent Expression of IGF1 in C57B6 Male Mice Treated with 17α-E2 – To
investigate the possible mechanism of 17α-E2 ’s lifespan extending properties and the interplay
with the GH/IGF1 axis we examined the hepatic and circulating levels of IGF1 and pulsatile GH
release in a cohort of C57B6 mice treated with 17α-E2 (Figure 1). In circulation, pulsatile release
of GH in C57B6 mice at week 0 and 15 show no difference with 17α-E2 treatment. Since GH
release is paired with IGF1 production we examined the IGF1 levels in circulation and hepatic
IGF1 production. With 17α-E2 treatment we see, surprisingly a significant increase in IGF1 both
in circulation and in the liver. This increase in IGF1 with 17α-E2 treatment is only seen in males
and not in females. This is surprising as IGF1 production is directly linked with GH release.
GH Independent Expression of IGF1 in GHRKO and Normal Male Mice Treated with
17α-E2 – With the observed GH independent regulation of IGF1 production seen in the C57B6
mice with 17α-E2 treatment we sought to further investigate this independent regulation of IGF1
production using a special mouse model, the GHRKO mouse model. In the GHRKO mice, we
first examined if hepatic and circulating levels of IGF1 levels were changed with the treatment
regimen and if this change was visible in both normal and GHRKO mice. As expected, both
circulating and hepatic IGF1 levels in both female and male GHRKO mice are diminished in
comparison to normal mice (Error! Reference source not found.) due to global lack of Ghr in
these mice. However, when examining treatment effects in male normal and GHRKO mice, we
see that with 17α-E2 treatment there is a significant increase in circulating IGF1 (Error!
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Reference source not found.A) We see also a similar result with hepatic IGF-1 mRNA
expression, there is a significant increase in both the normal and the GHRKO male mice with
17α-E2 treatment (

Figure 2 - 17α-E2 Treatment Increases Circulating and Hepatic IGF1 Levels in Males
C). Of additional interest is the effect of 17α-E2 on female GHRKO and normal mice, there is no
significant changes in IGF1 in circulation and in the liver in females with the treatment (

Figure 2 - 17α-E2 Treatment Increases Circulating and Hepatic IGF1 Levels in Males
A and D). This sex-specific effect of 17α-E2 has been previously observed and described
by several others in the field (5, 13, 14, 22)
Impact of 17α-E2 Treatment on Signaling Downstream of Growth Hormone and IGF1
Receptors - To further investigate possible pathways involved in the GH independent increase in
IGF1 seen with 17α-E2 treatment we examined genes downstream of the GHR in the JAK/STAT
pathway, which GH primarily signals through, in attempts to pinpoint alternate regulation of the
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classical pathway of IGF1 production. Starting with STAT5, treatment with 17α-E2 did not
significantly change mRNA levels of STAT5B across all eight groups (
Figure 3 – No change in hepatic Stat5b expression and AKT phosphorylation with 17α-E2
treatment
). Since no difference was observed at this level we examined downstream activation of
AKT, which was also found to have no differences with treatment across all eight groups as
indicated by phosphorylation levels (
Figure 3 – No change in hepatic Stat5b expression and AKT phosphorylation with 17α-E2
treatment
). Downstream in the signaling cascade, it is known that GH induces SOCS2 which
feeds-back to inhibit GH’s transcriptional action, thus serving as a negative regulator of its
action. It is expected then that levels of SOCS2 be quite low in GHRKO due to inactivation of
GHR signaling. This is reflected in the decreased relative expression levels of SOCS2 seen in
Figure 4 for both female and male GHRKO mice and significant treatment effects as calculated
in the three-way ANOVA. However, we do not see any significant changes in SOCS2 expression
with treatment in females or males (Figure 4). This suggest that 17α-E2 is acting independent of
the classical GH signaling pathway through a novel pathway to increase IGF1 production.
Effect of 17α-E2 treatment on Insulin Sensitivity - Based on previous studies implicating
17α-E2 treatment in improvements in glucose tolerance and insulin sensitivity (4, 22) we
examined plasma insulin levels at the end of the four month treatment as well as glucose levels
and calculated the Homeostatic Assessment of Insulin Resistance (HOMA) score for a measure
of insulin sensitivity. Plasma insulin levels in male GHRKO mice significantly decrease with
17α-E2 treatment (Figure 5A) and no change in normal males or female normal and GHRKO,
13

the latter consistent with previous observations that treatment effects are exclusive to males
(Figure 5C and D). Examining blood glucose levels at the end of 17α-E2 treatment, there are
significant decreases in both female normal and GHRKO mice with treatment (Figure 5D) and
no change in in male normal and GHRKO mice (Figure 5C).
Calculation of the HOMA score based on the insulin and glucose data in the GHRKO and
normal male and female mice show a significant decrease in HOMA score in the GHRKO male
mice with 17α-E2 treatment and significant treatment effects based on the Three-way ANOVA
in males (Figure 6A). Lower HOMA scores indicate increased insulin sensitivity and based on
the decreased in HOMA score observed we examined hepatic IRS1 expression, which is
downstream from the insulin receptor. We see that with 17α-E2 treatment there is significantly
increased IRS1 expression in normal male mice (Figure 6A). There is no significant effect of
treatment on IRS1 expression in male or female GHRKO or normal females (Figure 6B).
RNA-Sequencing Analysis of Liver - Based on the observed no difference in gene
expression downstream of GH/IGF1 signaling this suggests that 17α-E2 is acting through a novel
pathway yet to be elucidated to increase IGF1 production independent of GH. To further
investigate the molecular basis of the observed upregulation of hepatic IGF1 abundance in male
GHRKO mice, RNA analysis using next-generation sequencing was employed in liver from
normal and GHRKO male and female mice. Since we are interested in the molecular
mechanisms of 17α-E2 induced increase in GHR deficient livers and owing to the sex-specific
effect of this treatment and thus to keep within the scope of this thesis, we examine here
differentially regulated pathways that are altered in the GHRKO and show change with 17α-E2
treatment in male mice. For comparison purposes we show in (Figure 7) Venn diagrams of
14

differentially regulated pathways as well as up and down regulated genes across genders. We can
see here that when comparing normal males to normal females the number of upregulated genes,
interestingly enough, is relatively similar, with 86 and 83 genes significantly changed with 17αE2 treatment, respectively.
There is a total of seven upregulated pathways in GHRKO males and a total of nine
downregulated pathways in GHRKO with 17α-E2 treatment. In normal males, there are a total of
six upregulated pathways and seven downregulated pathways with 17α-E2 treatment. All three
pathways listed as common between normal and GHRKO males are commonly downregulated
for both groups. In order to gain a broader understanding of the spread of the data for this study
we generated a principle component analysis (PCA) plot for the RNAseq data which shows a
clustering of the normal male treated and untreated in a sector on their own (Figure 8).
Impact of 17α-E2 Treatment on Peroxisome Proliferator Activated Receptors in Liver- In
attempts to validate the upregulation of PPAR signaling with the RNAseq data previous
observations regarding the positive effect of 17α-E2 on metabolism we examined the hepatic
expression levels of the PPAR family of genes. The PPAR family of genes play pivotal roles in
lipid sensing and metabolism (23). Interestingly enough, we see there is increased hepatic
expression of PPARα in female GHRKO with treatment and no significant changes in PPARα
expression in normal females or male GHRKO and normal mice (Figure 9). This observation is
partially supported by the RNAseq data which showed upregulation of this pathway in normal
male mice. These observations collectively provides an insight into the mechanistic effects of
17α-E2 treatment on insulin sensitivity and point to a broader more complex regulation.
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Figure 1- 17α-E2 Treatment increases IGF1 levels in C57BL6 Mice with no change in GH
pulsativity
Circulating IGF1 and hepatic protein and mRNA IGF1 expression and pulsatile GH
release in control and 17α-E2 treated male C57B6 mice. A. Circulating IGF1 in control (CON)
and 17α-E2 treated mice as measured by ELISA. B. Hepatic protein and mRNA levels of IGF1
as measured by ELISA and qPCR, respectively. C. Pulsatile GH release in control and 17α-E2
treated mice at week 0 and week 15. Results are presented as the mean ±SEM. Bars labeled with
asterisk show p values using Student’s t-test; *p<0.05
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Figure 2 - 17α-E2 Treatment Increases Circulating and Hepatic IGF1 Levels in Males
Circulating and Hepatic expression of IGF1 in GHRKO and normal Male and Female
Mice. A. Circulating IGFI levels in normal untreated (n=8) and treated (n=12) male mice and
GHRKO treated (n=10) and untreated (n=9) male mice as measured by ELISA. B. Circulating
IGFI levels in normal untreated (n=11) and treated (n=11) female mice and GHRKO treated
(n=9) and untreated (n=9) female mice as measured by ELISA. C. Hepatic IGFI levels in normal
untreated and treated male mice and GHRKO treated and untreated male mice as measured by
qPCR. D. Hepatic IGFI levels in normal untreated and treated male mice and GHRKO treated
and untreated male mice as measured by qPCR. All results are presented as the mean ±SEM.
Bars labeled with asterisk show p values using Student’s t-test; *p<0.05.
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Figure 3 – No change in hepatic Stat5b expression and AKT phosphorylation with 17α-E2
treatment
Hepatic Stat5b expression and AKT phosphorylation (S473) levels in treated and
untreated male and female GHRKO and normal mice. A. Relative expression levels of Stat5b in
liver of normal and GHRKO male mice with and without 17α-E2 treatment. B. Relative
expression levels of Stat5b in liver of normal and GHRKO female mice with and without 17α-E2
treatment. C. AKT phosphorylation levels in liver of normal and GHRKO male mice with and
without 17α-E2 treatment. D. AKT phosphorylation levels in liver of normal and GHRKO
female mice with and without 17α-E2 treatment. All results are presented as the mean ±SEM
with n equivalent to that described in the caption of Figure 1 this is true for Figure 4 and Figure 5
as well.
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Figure 4 - Downregulation of SOCS2 in Liver of GHRKO Mice
Hepatic SOCS2 expression in treated and untreated male and female GHRKO and normal
mice. A. Relative expression levels of SOCS2 in liver of normal and GHRKO male mice with
and without 17α-E2 treatment. B. Relative expression levels of SOCS2 in liver of normal and
GHRKO female mice with and without 17α-E2 treatment. All results are presented as the mean
±SEM.
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Figure 5- Glucose levels decrease and Insulin levels decrease in males with 17α-E2 Treatment
Blood glucose levels and plasma insulin levels measured after the four months of
treatment with 17α-E2. A. Plasma insulin levels in normal and GHRKO male mice with and
without 17α-E2 treatment. B. Plasma insulin levels in normal and GHRKO female mice with and
without 17α-E2 treatment. C. Blood glucose levels in normal and GHRKO male mice with and
without 17α-E2 treatment. All results are presented as the mean ±SEM. Bars labeled with
asterisk show p values using Student’s t-test; *p<0.05
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Figure 6 - Effect of 17α-E2 on insulin signaling
Homeostatic Assessment of Insulin Resistance and Hepatic IRS1 expression levels in
treated and untreated male and female GHRKO and normal mice C. Relative expression of IRS1
in liver of normal and GHRKO male mice with and without 17α-E2 treatment. D. Relative
expression of IRS1 in liver of normal and GHRKO female mice with and without 17α-E2
treatment. Lower HOMA score indicates higher insulin sensitivity and is calculated by
multiplication of fasting insulin and fasting glucose and dividing by 22.5. All results are
presented as the mean ±SEM. Bars labeled with asterisk show p values using Student’s t-test;
*p<0.05.
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Figure 7 - Differentially Regulated Genes and Pathways Between Normal Males and Females in
when Comparing Treated and Untreated Mice
Genes and pathways altered with 17α-E2 treatment, a schematic comparison across
groups. A. Number of genes upregulated in normal male and female mice with 17α-E2 treatment
and those shared by the two groups. B. Number of genes downregulated in normal male and
female mice with 17α-E2 treatment and those shared by the two groups. C. Number of pathways
differentially regulated in normal male and female mice with 17α-E2 treatment. D. Number of
pathways altered with 17α-E2 treatment a comparison between GHRKO and normal male mice.
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Figure 8 – Principle Component Analysis of RNA-sequencing data of the eight experimental
groups
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Table 2- Differentially Regulated Pathways in GHRKO and Normal Male Mice with 17α-E2
Treatment (arrows indicate up or down regulation of the pathway)

Regulated Pathways in Male GHRKO Mice
mmu00230
mmu00480
mmu00500
mmu00590
mmu04110
mmu03420
mmu03440
mmu04020
mmu04270
mmu04514
mmu04610
mmu04630
mmu04640
mmu04660
mmu04672
mmu04973

Purine metabolism
Glutathione metabolism
Starch and sucrose metabolism
Arachidonic acid metabolism
Cell cycle
Nucleotide excision repair
Homologous recombination
Calcium signaling pathway
Vascular smooth muscle contraction
Cell adhesion molecules (CAMs)
Complement and coagulation cascades
Jak-STAT signaling pathway
Hematopoietic cell lineage
T cell receptor signaling pathway
Intestinal immune network for IgA production
Carbohydrate digestion and absorption

↓
↓
↓
↑
↓
↓
↓
↑
↑
↑
↑
↑
↑
↑
↑
↓

Commonly Regulated Pathways between Male GHRKO and Normal Mice
mmu00100
mmu00900
mmu03030

Steroid biosynthesis
Terpenoid backbone biosynthesis
DNA replication

↓
↓
↓

Regulated Pathways in Normal Male Mice
mmu00140
mmu00190
mmu00240
mmu00250
mmu02010
mmu03040
mmu03050
mmu04012
mmu04070
mmu04122
mmu04141
mmu04614
mmu04976
mmu03320

Steroid hormone biosynthesis
Oxidative phosphorylation
Pyrimidine metabolism
Alanine, aspartate and glutamate metabolism
ABC transporters
Spliceosome
Proteasome
ErbB signaling pathway
Phosphatidylinositol signaling system
Sulfur relay system
Protein processing in endoplasmic reticulum
Renin-angiotensin system
Bile secretion
PPAR signaling pathway
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↑
↓
↓
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Figure 9 -Regulatory Role of 17α-E2 on Peroxisome Proliferator Activated Receptors in Liver
PPARγ and PPARα expression in levels in treated and untreated male and female
GHRKO and normal mice. A. Relative expression of PPARγ in liver of normal and GHRKO
male mice with and without 17α-E2 treatment. B. Relative expression of PPARγ in liver of
normal and GHRKO female mice with and without 17α-E2 treatment. C. Relative expression of
PPARα in liver of normal and GHRKO male mice with and without 17α-E2 treatment. D.
Relative expression of PPARα in liver of normal and GHRKO male mice with and without 17αE2 treatment. All results are presented as the mean ±SEM. Bars labeled with asterisk show p
values using Student’s t-test; *p<0.05, **p<0.01.
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CHAPTER FIVE: DISCUSSION
The well-established idea in the field of GH/IGF1 research is the inextricable link
between IGF1 production by the liver, which is the primary source of IGF1 production, to GH
signaling. This signaling cascade and the downstream effects of it are responsible in maintaining
glucose homeostasis and imbalance causes a myriad of metabolic disorders and dysregulation of
the signaling is common with age and age-associated obesity. Traditionally, negative modulation
of GH/IGF1 signaling increases lifespan and this is apparent in studies involving long-living
models for aging studies including GHRKO and Ames Dwarf mice. These long-lived models are
characterized by decreased levels of GH, IGF1 and insulin. In this study, we see IGF1 increases
while GH remains the same with 17α-E2 treatment in the GHRKO mice and yet there is
increased insulin sensitivity. This questions traditional ideas about the effects of negative
modulation of GH/IGF1 signaling in increasing lifespan. In both normal and GHRKO male mice
with 17α-E2 treatment IGF1 increases, supporting our hypothesis. Throughout this study we see
a sex-specific divergence in 17α-E2 treatment effects, with effects seen only in males. This was
previously observed by others in the field in the context of lifespan and aging and one possible
explanation for the lifespan extension aspect in response to the treatment is that it is well known
that females across several species live longer than males (24) and it is likely due to increased
endogenous levels of estrogens compared to males so treatment at this dosage does not render
any effects.
Based on our results it can be said that the 17α-E2 treatment is increasing IGF1 in
GHRKO mice. This is of particular interest because it has been well established that IGF1
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expression is practically completely dependent on GH action and the visible increase in IGF1
expression in GHRKO mice would then suggest an alternate pathway of IGF1 production as
mediated by 17α-E2 treatment. These results are also consistent with the relative gene expression
data on genes downstream of classical GH, IGF1 and Insulin signaling in which we find no
significant changes including SOCS2, STAT5b and AKT activation, pointing again to a novel
pathway which 17α-E2 acts through to increase IGF1 production (Figure 3 and Figure 4). The
GH independent IGF1 production with 17α-E2 treatment is also seen in C57B6 mice and further
supported by data the growth-hormone resistant GHRKO mice (Figure 1 and Figure 2).
Examining one previous study which described the treatment of GHRKO mice with
17βE2 in the context of bone growth (6) Here they describe an increase in mRNA IGF1 levels
which is similar to what we observed here with the estrogen treatment and an increase in STAT5
activation which is not consistent with our data. This is likely because they used the enantiomer
of 17α-E2, 17βE2 for treatment. Although, this lends support to an underlying mechanism of
estrogen action on the GH/IGF1 axis which may underlie sex differences in metabolism with
aging.
Using this as a springboard for the underlying sexual dimorphisms with treatment,
comparison of our sequencing data with metabolomics data from a recent study treating castrated
males and ovariectomized females with 17α-E2 we see some overlap. They describe a change in
the metabolites associated with the urea cycle including glutamine and alanine in mice treated
with 17α-E2. When comparing this to our RNAseq output we also see a change in Alanine,
aspartate and glutamate metabolism (Table 2) they noted that the positive effects of treatment are
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ablated when gonads are removed in the males pointing to a complex interaction of sex hormone
production in the mice with the beneficial effects of 17α-E2 treatment (5).
The principle component analysis of the RNAseq data uncovers an interesting
relationship with all the normal male treated and untreated mice clustering on their own, this is
possibly due to the differential regulation of IGF1 production through a novel pathway in these
mice and a dependence of treatment on male sex hormones as described by Michael et al. Upon
further examination of the regulated pathways in our data with treatment in males, in the
pathways distinct to GHRKO mice we see there is positive regulation of calcium signaling and
JAK/STAT signaling. This can be explained by the signaling pathway by which estrogens act,
they initiate signaling via MAPK and PI3K to increase intracellular calcium. With regard to the
JAK/STAT pathway upregulation this could provide a clue as to the alternative regulation of
IGF1 production as GH signals through this pathway. Going along with this pathway in the
context of regulated pathways in normal mice with treatment we see there is upregulation of the
PI3K pathway. This observation in the sequencing data is supported by the increase in mRNA
IRS1 expression levels (Figure 4A) which is only seen in normal males. IRS1 connects insulin
receptor activation to downstream PI3K signaling cascades and subsequent transport of glucose.
Increased PI3K activation in the normal mice can suggest increased insulin signaling and may
contribute to increased insulin sensitivity. This increase in insulin sensitivity with 17α-E2
treatment is further supported by the decrease in HOMA scores in male mice (Figure 6) In
addition, results seen with increases in PPARγ with treatment in normal males suggests enhanced
lipid metabolism in these animals lending itself to the idea that 17α-E2 enhances metabolic
function (Figure 5A).
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This can lead us to imagine that 17α-E2 is working on different parts of pathways to lead
to a similar result overall male mice regarding positive metabolic effects. It is important to note
that when comparing GHRKO males to females, the only pathway common between the two
with treatment is the calcium signaling pathway and this could suggest again that since estrogens
work to increase intracellular calcium the exogenous origins of estrogen via 17α-E2 treatment
worked to increase levels in females to account for this upregulation. Although the PI3K
pathway is only upregulated with treatment in normal males, it can lend support to previous
findings in the field showing positive metabolic effects of treatment only in males.
Turning to other alternatively regulated pathways with 17α-E2 treatment in the normal
male mice, we see an upregulation of the Renin-Angiotensin pathway. This pathway is thought
to negatively affect insulin signaling but upon closer examination of the individual genes
upregulated in the Renin-Angiotensin pathway in the Normal male mice with treatment we see
those that are upregulated are involved with Angiotensin (1–7), which is derived from the
metabolism of Angiotensin I. In contrast, other parts of the pathway including Angiotensin II
which negatively modulates insulin signaling on multiple levels including IRS1, AKT, and PI3K
(25, 26) were unchanged. Given that there exists a crosstalk between renin-angiotensin and
insulin signaling, and the upregulation of this system could be indicative of enhanced insulin
signaling, it is plausible that 17α-E2 promotes insulin sensitivity. Upregulation of the proteasome
pathway in normal male mice could account for the no visible change in STAT5b observed in the
qPCR data as it would indicate increased proteasome mediated protein degradation and
subsequent downregulation of STAT5 (27).

29

This observation suggests a highly complex mechanism of action that could point to an
interplay of 17α-E2 treatment with other sex hormones as was recently published about in mice
whose gonads were removed (5). Many of the other pathways up and downregulated in the male
GHRKO and normal mice have an unclear purpose in the range for which this study was
conducted and we have included them here in the hope that this study will lay the ground work
for a better understanding of the 17α-E2 mechanisms of action as it poises itself as a possible
therapeutic for age-related metabolic dysfunction.
Ultimately, to determine the origins of this sex-specific effect of 17α-E2 on GH
independent IGF1 synthesis future studies with the removal of gonads in a cohort of female and
male GHRKO mice similar to work which was conducted by Garratt et. al. is recommended.
This would provide further information regarding the pathways with which 17α-E2 acts to
increase IGF1 independent of GH and isolate the sex-specific factors contributing to the positive
metabolic effects seen with treatment. Given that 17α-E2 has been shown to extend lifespan
preferentially in males it would be interesting to conduct a long-term treatment, again with a
cohort of GHRKO males and females to investigate the longevity aspect as this study was
limited to a four-month period of treatment. Studying the long-term effects of 17α-E2 in
GHRKO mice can give insight into how this hormonal treatment can affect these mice with
regard to metabolic function with age and given the complex interplay with aging IGF1/GH
secretion can raise questions about how 17α-E2 affects their levels over a lifespan.
The present study establishes an upregulation of IGF1 by a hormone other than GH
which is a novel and groundbreaking observation in the field. Based off of these findings that
17aE2 works through a novel GH independent pathway to positively regulate insulin sensitivity
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and other findings in the field regarding the lifespan extending potential and positive metabolic
effects and given its nature as a non-feminizing estrogen, 17α-E2 has promising potential as a
therapeutic retaining the positive metabolic effects while reducing potential complications
associated with feminizing hormones.
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